SP0133 ANCA and their environment

SP0133 ANCA and their environment

Bibliographic Details
Main Author:	Luqmani, R
Format:	Conference item
Published:	BMJ Publishing Group 2017

Similar Items

Maintenance of clinical remission in ANCA-associated vasculitis.
by: Luqmani, R
Published: (2013)

Towards diagnostic criteria for the ANCA-associated vasculitides.
by: Luqmani, R
Published: (2007)

Damage assessment in ANCA-associated vasculitis.
by: Bhamra, K, et al.
Published: (2012)

ANCA POSITIVE AND ANCA NEGATIVE MICROSCOPIC POLYARTERITIS
by: Adu, D, et al.
Published: (1994)

Opinion: Maintenance of clinical remission in ANCA-associated vasculitis
by: Luqmani, R
Published: (2013)

Outcome measures in ANCA-associated vasculitis.
by: Suppiah, R, et al.
Published: (2010)

Does a gating policy for ANCA overlook patients with ANCA associated vasculitis? An audit of 263 patients.
by: Arnold, D, et al.
Published: (2010)

ANCA-associated vasculitis: Where can we go from here?
by: Luqmani, R
Published: (2010)

Cutaneous manifestations of ANCA-associated vasculitis
by: Chiesafuxench, Z, et al.
Published: (2016)

Cardiovascular outcomes in ANCA associated vasculitis
by: Mukhtyar, C, et al.
Published: (2008)

Diagnosis and management of ANCA associated vasculitis.
by: Berden, A, et al.
Published: (2012)

The prognostic value of BVAS and VDI in ANCA-AAV
by: Suppiah, R, et al.
Published: (2011)

Classification criteria for the anca-associated vasculitides
by: Robson, J, et al.
Published: (2019)

DEVELOPMENT OF DIAGNOSTIC CRITERIA FOR PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
by: McLaren, J, et al.
Published: (2003)

Positive predictive value of anti-neutrophil cytoplasmic antibody (ANCA) testing for ANCA-associated systemic vasculitis (AASV) in a routine clinical setting
by: McLaren, J, et al.
Published: (2001)

P01.33. A new development of Triterpene Acids-containing extracts from Viscum album L. displays synergistic induction of apoptosis in childhood leukemia
by: Delebinski C, et al.
Published: (2012-06-01)

Global ethnic and geographic idfferences in the clinical features of ANCA-associated vasculitis
by: Pearce, F, et al.
Published: (2016)

Predicting cardiovascular events in patients with newly diagnosed ANCA-AAV
by: Suppiah, R, et al.
Published: (2011)

Predictors of renal involvement in ANCA associated vasculitis
by: Kronbichler, A, et al.
Published: (2018)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
by: Luqmani, R, et al.
Published: (2007)

Adjunctive plasma exchange is superior to methylprednisolone in acute renal failure due to ANCA-associated glomerulonephritis.
by: Luqmani, R, et al.
Published: (2002)

A four year analysis of variation in use of the anti-neutrophil cytoplasmic antibody (ANCA) test as a screening tool for ANCA-associated systemic vasculitis (AAV) in a teaching hospital.
by: McLaren, J, et al.
Published: (2000)

A multi-centre randomised trial of cyclophosphamide versus azathioprine during remission in ANCA-associated systemic vasculitis (Cycazarem).
by: Luqmani, R, et al.
Published: (1999)

Explaining fatigue in ANCA-associated vasculitis.
by: Basu, N, et al.
Published: (2013)

Explaining fatigue in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

Cutaneous manifestations of ANCA-associated vasculitis are common, varied, and associated with systemic disease
by: Micheletti, R, et al.
Published: (2017)

Cardiovascular disease incidence and risk factors in ANCA-associated primary systemic vasculitis (AASV)
by: Salisbury, E, et al.
Published: (2003)

Long-term survival of ANCA-associated vasculitis
by: Flossmann, O, et al.
Published: (2009)

Markers for work disability in ANCA-associated vasculitis
by: Basu, N, et al.
Published: (2013)

INCIDENCE OF NON-FATAL CLINICAL CORONARY EVENTS IN PRIMARY ANCA-ASSOCIATED SYSTEMIC VASCULITIS (AASV)
by: Salisbury, E, et al.
Published: (2003)

CARDIOVASCULAR AND CEREBROVASCULAR DISEASE INCIDENCE AND RISK FACTORS IN ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV)
by: Salisbury, E, et al.
Published: (2004)

Comparison of disease activity measures for ANCA-associated vasculitis.
by: Merkel, P, et al.
Published: (2004)

DIAGNOSTIC CRITERIA FOR ANCA-ASSOCIATED PRIMARY SYSTEMIC VASCULITIS (AASV) IN PATIENTS PRESENTING WITH ACUTE PULMONARY AND/OR RENAL DISEASE
by: McLaren, J, et al.
Published: (2004)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
by: Jones, R, et al.
Published: (2010)

Incidence of non-fatal clinical coronary events in primary ANCA-associated systemic vasculitis (aasv)
by: Salisbury, E, et al.
Published: (2003)

BSR and BHPR guideline for the management of adults with ANCA-associated vasculitis.
by: Ntatsaki, E, et al.
Published: (2014)

BSR and BHPR guidelines for the management of adults with ANCA associated vasculitis.
by: Lapraik, C, et al.
Published: (2007)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
by: Zachary S. Wallace, et al.
Published: (2019-12-01)

CONTEXTUALISING QUALITY OF LIFE IN ANCA ASSOCIATED VASCULITIS (AAV)
by: Basu, N, et al.
Published: (2012)

The characterisation and determinants of quality of life in ANCA associated vasculitis.
by: Basu, N, et al.
Published: (2014)